Athanor Capital’s Sutro Biopharma STRO Stock Holding History

Athanor Capital’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,128	Closed	-$679K	–	1031
2020 Q4	$679K	Buy	+3,128	New	+$518K	0.02%	400

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Athanor Capital's STRO Position: Q1 2021 in Review

Athanor Capital sold out of Sutro Biopharma (STRO) in Q1 2021, closing a stake of 3,128 shares — an estimated $679K sold.

Athanor Capital first reported a position in STRO in Q4 2020 and held it in 1 quarter. The position peaked at $679K in Q4 2020. 138 funds tracked by Wall St. Rank hold STRO as of Q1 2021.

Athanor Capital reported no remaining Sutro Biopharma position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 3,128 Sutro Biopharma shares in Q1 2021, an estimated $679K.
Athanor Capital first reported a position in Sutro Biopharma in Q4 2020 and held it in 1 quarter.
Athanor Capital's Sutro Biopharma position peaked at $679K in Q4 2020.
138 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.